Filana Therapeutics, Inc. FLNA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -68.59% | -77.20% | -77.92% | -65.64% | -40.14% |
| Gross Profit | 68.59% | 77.20% | 77.92% | 65.64% | 40.14% |
| SG&A Expenses | -23.52% | -34.04% | -64.78% | -62.67% | -55.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.27% | -56.68% | -68.88% | -62.28% | -46.71% |
| Operating Income | 46.27% | 56.68% | 68.88% | 62.28% | 46.71% |
| Income Before Tax | 60.20% | 65.67% | -7.02% | -273.73% | -500.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.20% | 65.67% | -7.02% | -273.73% | -500.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.20% | 65.67% | -7.02% | -273.73% | -500.27% |
| EBIT | 46.27% | 56.68% | 68.88% | 62.28% | 46.71% |
| EBITDA | 47.08% | 57.27% | 69.31% | 62.62% | 46.84% |
| EPS Basic | 60.28% | 65.76% | -6.95% | -327.53% | -505.98% |
| Normalized Basic EPS | 46.89% | 57.61% | 44.68% | -65.54% | -157.13% |
| EPS Diluted | 60.26% | 65.73% | -7.05% | -30.14% | -59.80% |
| Normalized Diluted EPS | 46.89% | 57.61% | 44.68% | -62.39% | -151.57% |
| Average Basic Shares Outstanding | 0.21% | 0.30% | 1.41% | 4.27% | 7.59% |
| Average Diluted Shares Outstanding | 0.21% | 0.30% | 1.41% | 3.65% | 6.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |